Skip to main content
. Author manuscript; available in PMC: 2025 Feb 18.
Published in final edited form as: Am J Physiol Heart Circ Physiol. 2022 Jul 22;323(3):H424–H436. doi: 10.1152/ajpheart.00121.2022

Figure 2: Skeletal muscle-specific PFKFB3 expression increased ischemic muscle force levels but did not change myofibers area.

Figure 2:

(A) Force-frequency curves of the EDL muscle in male and female mice treated with either AAV9-HSA-GFP or AAV9-HSA-PFKFB3 (n=5-6/group/sex). *P<0.05 vs. AAV9-HSA-GFP using two-way ANOVA. (B) Peak specific force in the EDL muscle (n=5-6/group/sex). (C) Representative H&E images of the TA muscle from sham (non-ischemic) and AAV-treated ischemic muscles. (D) Histograms of the TA myofiber CSA presented as a percentage of frequency distribution in both male and female mice (E). Mean TA myofiber area in male and female mice (n=5-6/group/sex). (F) Histogram of EDL myofiber CSA presented as a percentage of frequency distribution in both male and female mice (G) Mean EDL myofiber area in male and female mice (n=5-6/group/sex). Error bars represent SD. Panels B, E and G were analyzed using two-way ANOVA.